Advanced search
Combine gene, variant, phenotype, region and year filters
Every result shows the extracted entities next to the sentences that support them; rows for the searched entities come first.
Transparent by designEvery result links extracted entities to its source sentence and publication identifier.
Knowledge-base search
About your search
EGFR and breast cancer are reported together in 57 articles.
Gene
EGFR
- HGNC
- HGNC:3236
290articles
290mentions
5variants with confirmed gene link
Most co-reported phenotypes (articles)
lung cancer 74breast cancer 57colorectal cancer 27lymphoma 6hepatocellular carcinoma 5diabetes mellitus 4leukemia 4gastric cancer 3
Reported variants (articles · ClinVar status)
Phenotype
Breast cancer
1,211articles
1,211mentions
12co-reported genes shown
Most co-reported genes (articles)
Counts are literature co-mentions in SaudiVarKB, not clinical or causal assertions. Gene details: HGNC; variant status: ClinVar via dbSNP.
Publications
57 records shown · first 60Erucin Targets Oncogenic Signaling Pathways in Triple-Negative Breast Cancer: An Integrated Network Pharmacology and In Vitro Study.
PMID 42195263 | PMCID PMC13208285 | DOI 10.3390/life16050708 · Life (Basel, Switzerland) · 2026 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Protein-protein interaction analysis identified ten hub genes, including AKT1, STAT3, EGFR, and MMP9, representing highly connected nodes within the predicted interaction network.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Erucin Targets Oncogenic Signaling Pathways in Triple-Negative Breast Cancer: An Integrated Network Pharmacology and In Vitro Study.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | AKT1 | “Protein-protein interaction analysis identified ten hub genes, including AKT1, STAT3, EGFR, and MMP9, representing highly connected nodes within the predicted interaction network.” | 0.98 | hgnc_dict_v1 |
| gene | STAT3 | “Protein-protein interaction analysis identified ten hub genes, including AKT1, STAT3, EGFR, and MMP9, representing highly connected nodes within the predicted interaction network.” | 0.98 | hgnc_dict_v1 |
Multitargeted comparative evaluation suggests 2-Aoeobenoxmide shows favourable in silico binding compared to Tucatinib against ERα, HER2, AKT1, EGFR, and PIK3CA in breast cancer.
PMID 42310133 | PMCID PMC13547228 | DOI 10.1038/s41598-026-57604-0 · Scientific reports · 2026 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Multitargeted comparative evaluation suggests 2-Aoeobenoxmide shows favourable in silico binding compared to Tucatinib against ERα, HER2, AKT1, EGFR, and PIK3CA in breast cancer.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Multitargeted comparative evaluation suggests 2-Aoeobenoxmide shows favourable in silico binding compared to Tucatinib against ERα, HER2, AKT1, EGFR, and PIK3CA in breast cancer.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | AKT1 | “Multitargeted comparative evaluation suggests 2-Aoeobenoxmide shows favourable in silico binding compared to Tucatinib against ERα, HER2, AKT1, EGFR, and PIK3CA in breast cancer.” | 0.98 | hgnc_dict_v1 |
| gene | PIK3CA | “Multitargeted comparative evaluation suggests 2-Aoeobenoxmide shows favourable in silico binding compared to Tucatinib against ERα, HER2, AKT1, EGFR, and PIK3CA in breast cancer.” | 0.98 | hgnc_dict_v1 |
CAR-T cell therapy in breast cancer management: expanding horizon and overcoming challenges beyond hematologic cancers.
PMID 41944897 | DOI 10.1007/s11033-026-11752-8 · Molecular biology reports · 2026 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Specifically, we discuss the critical components of CAR-T design, including antigen selection (e.g., HER2, MUC1, and EGFR), CAR structure optimisation with intracellular signalling domains, and genetic engineering techniques like CRISPR and TALENs.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “CAR-T cell therapy in breast cancer management: expanding horizon and overcoming challenges beyond hematologic cancers.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | MUC1 | “Specifically, we discuss the critical components of CAR-T design, including antigen selection (e.g., HER2, MUC1, and EGFR), CAR structure optimisation with intracellular signalling domains, and genetic engineering techniques like CRISPR and TALENs.” | 0.98 | hgnc_dict_v1 |
Untargeted UHPLC-Q exactive orbitrap HRMS-based network pharmacology for the discovery of anti-breast cancer compounds from spatholobus littoralis stems fractions and experimental validation.
PMID 40452618 | DOI 10.1080/14786419.2025.2511158 · Natural product research · 2026 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Several bioactive compounds from the aqueous fraction exhibited anti-breast cancer activity via EGFR tyrosine kinase inhibition.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Spatholobus littoralis has been traditionally used by the Dayak tribe as a medicine to treat breast cancer.” | 0.98 | phenotype_alias_lexicon_v2 |
Design and synthesis of novel isatin-isoniazidhydrazone hybrid-based 1,2,3-triazoles as dual EGFR/PARP-1 inhibitors and apoptosis inducers in breast cancer cells.
PMID 42001586 | DOI 10.1016/j.bioorg.2026.109859 · Bioorganic chemistry · 2026 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Design and synthesis of novel isatin-isoniazidhydrazone hybrid-based 1,2,3-triazoles as dual EGFR/PARP-1 inhibitors and apoptosis inducers in breast cancer cells.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Design and synthesis of novel isatin-isoniazidhydrazone hybrid-based 1,2,3-triazoles as dual EGFR/PARP-1 inhibitors and apoptosis inducers in breast cancer cells.” | 0.98 | phenotype_alias_lexicon_v2 |
Genomic Landscape of Advanced Solid Tumors in Middle East and North Africa Using Circulating Tumor DNA in Routine Clinical Practice.
PMID 39342926 | PMCID PMC12140595 | DOI 10.1159/000541571 · Oncology · 2025 · 14 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “RESULTS: In the pan-cancer group, TP53 (58.5%), EGFR (20.4%), and KRAS (18.9%) were the most frequently mutated genes.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “In patients with breast cancer, PIK3CA (35.3%), ESR1 (21.7%), and BRCA1/2 (13.3%) had the most prevalent alterations among NCCN-recommended genes.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | TP53 | “RESULTS: In the pan-cancer group, TP53 (58.5%), EGFR (20.4%), and KRAS (18.9%) were the most frequently mutated genes.” | 0.98 | hgnc_dict_v1 |
| gene | KRAS | “RESULTS: In the pan-cancer group, TP53 (58.5%), EGFR (20.4%), and KRAS (18.9%) were the most frequently mutated genes.” | 0.98 | hgnc_dict_v1 |
Investigating the genetic landscape of cancer in Jordan: a step toward personalized care.
PMID 40604932 | PMCID PMC12220200 | DOI 10.1186/s40001-025-02799-7 · European journal of medical research · 2025 · 9 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “While somatic mutations such as KRAS and EGFR were commonly reported in tumor studies, our primary focus is on germline PSVs that may indicate population-specific genetic risks, including BRCA1 exon 11 mutations in breast cancer and p.Gly12Asp in KRAS for colorectal cancer.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “While somatic mutations such as KRAS and EGFR were commonly reported in tumor studies, our primary focus is on germline PSVs that may indicate population-specific genetic risks, including BRCA1 exon 11 mutations in breast cancer and p.Gly12Asp in KRAS for colorectal cancer.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | BRCA1 | “Breast, colorectal, and lung cancers were the most studied, with BRCA1/2 and TP53 among the most frequently mutated genes.” | 0.98 | hgnc_dict_v1 |
| gene | TP53 | “Breast, colorectal, and lung cancers were the most studied, with BRCA1/2 and TP53 among the most frequently mutated genes.” | 0.98 | hgnc_dict_v1 |
Tailored therapies for triple-negative breast cancer: current landscape and future perceptions.
PMID 40029385 | DOI 10.1007/s00210-025-03896-4 · Naunyn-Schmiedeberg's archives of pharmacology · 2025 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “The molecular landscape of TNBC is covered in the first section, which keeps the focus on transcriptome and genomic profiling while highlighting key molecular targets like mutations in the BRCA1/2, PIK3CA, androgen receptors (AR), epidermal growth factor receptors (EGFR), and immunological checkpoint molecules.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Tailored therapies for triple-negative breast cancer: current landscape and future perceptions.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | BRCA1 | “The molecular landscape of TNBC is covered in the first section, which keeps the focus on transcriptome and genomic profiling while highlighting key molecular targets like mutations in the BRCA1/2, PIK3CA, androgen receptors (AR), epidermal growth factor receptors (EGFR), and immunological checkpoint molecules.” | 0.98 | hgnc_dict_v1 |
| gene | PIK3CA | “The molecular landscape of TNBC is covered in the first section, which keeps the focus on transcriptome and genomic profiling while highlighting key molecular targets like mutations in the BRCA1/2, PIK3CA, androgen receptors (AR), epidermal growth factor receptors (EGFR), and immunological checkpoint molecules.” | 0.98 | hgnc_dict_v1 |
PD-L1 targeting in triple negative breast cancer: in silico and in vitro validation of wasp venom peptide MP-1.
PMID 41284169 | DOI 10.1007/s12032-025-03133-1 · Medical oncology (Northwood, London, England) · 2025 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Gene expression studies showed significant down regulation of PD-L1, EGFR, STAT3, BCL2 and Ki-67, while the up regulation of Caspase-3, Caspase-9 and BAX (p < 0.0001).” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “PD-L1 targeting in triple negative breast cancer: in silico and in vitro validation of wasp venom peptide MP-1.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | STAT3 | “Gene expression studies showed significant down regulation of PD-L1, EGFR, STAT3, BCL2 and Ki-67, while the up regulation of Caspase-3, Caspase-9 and BAX (p < 0.0001).” | 0.98 | hgnc_dict_v1 |
| gene | BCL2 | “Gene expression studies showed significant down regulation of PD-L1, EGFR, STAT3, BCL2 and Ki-67, while the up regulation of Caspase-3, Caspase-9 and BAX (p < 0.0001).” | 0.98 | hgnc_dict_v1 |
Male Breast Cancer: Epidemiology, Diagnosis, Molecular Mechanisms, Therapeutics, and Future Prospective.
PMID 41502531 | PMCID PMC12774558 | DOI 10.32604/or.2025.068238 · Oncology research · 2025 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Molecular mechanisms involve hormonal signaling, HER2/epidermal growth factor receptor (EGFR) pathways, tumor suppressor gene alterations, and epigenetic changes.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Male Breast Cancer: Epidemiology, Diagnosis, Molecular Mechanisms, Therapeutics, and Future Prospective.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | BRCA1 | “Major risk factors include hormonal imbalance, radiation exposure, obesity, alcohol use, and Breast Cancer Gene 1 and 2 (BRCA1/2) mutations.” | 0.98 | hgnc_dict_v1 |
| gene | CDK4 | “While standard treatments mirror those for female breast cancer, emerging options such as cyclin-dependent kinase 4 and 6 (CDK4/6), and poly(ADP-ribose) polymerase (PARP) inhibitors, immunotherapy, and precision medicine are reshaping management.” | 0.98 | hgnc_dict_v1 |
An innovative approach to development of new pyrazolylquinolin-2-one hybrids as dual EGFR and BRAFV600E inhibitors.
PMID 40056327 | PMCID PMC12638379 | DOI 10.1007/s11030-025-11127-4 · Molecular diversity · 2025 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “An innovative approach to development of new pyrazolylquinolin-2-one hybrids as dual EGFR and BRAFV600E inhibitors.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “The promising hybrids 4d-g are screened by MTT assays on three cancer cell lines: leukemia (MOLT-4), lung cancer (HOP-92), and breast cancer (T47D), with IC50 values ranging from 4.982 ± 0.2 to 36.52 ± 1.46 µM compared to Staurosporine, with compound 4e being the most effective.” | 0.98 | phenotype_alias_lexicon_v2 |
| phenotype | lung cancer | “The promising hybrids 4d-g are screened by MTT assays on three cancer cell lines: leukemia (MOLT-4), lung cancer (HOP-92), and breast cancer (T47D), with IC50 values ranging from 4.982 ± 0.2 to 36.52 ± 1.46 µM compared to Staurosporine, with compound 4e being the most effective.” | 0.98 | phenotype_alias_lexicon_v2 |
| phenotype | leukemia | “The promising hybrids 4d-g are screened by MTT assays on three cancer cell lines: leukemia (MOLT-4), lung cancer (HOP-92), and breast cancer (T47D), with IC50 values ranging from 4.982 ± 0.2 to 36.52 ± 1.46 µM compared to Staurosporine, with compound 4e being the most effective.” | 0.98 | phenotype_alias_lexicon_v2 |
Exploring the Anticancer Potential of Lamivudine-Loaded Polymeric Nanoparticles: In Vitro Cytotoxicity, Tissue Deposition, Biochemical Impact In Vivo, and Molecular Simulations Analysis.
PMID 40384113 | PMCID PMC12175167 | DOI 10.1021/acsabm.5c00182 · ACS applied bio materials · 2025 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Finally, we performed theoretical studies of molecular docking, molecular dynamics and interactions between lamivudine and key proteins regulating necroptosis, including epidermal growth factor receptor (EGFR), receptor-interacting protein kinase 1 (RIPK1), and receptor-interacting protein kinase 3 (RIPK3).” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Recently, studies have also shown that lamivudine (3TC) can induce apoptosis in cancer cells and inhibit their proliferation, including breast cancer.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | RIPK1 | “Finally, we performed theoretical studies of molecular docking, molecular dynamics and interactions between lamivudine and key proteins regulating necroptosis, including epidermal growth factor receptor (EGFR), receptor-interacting protein kinase 1 (RIPK1), and receptor-interacting protein kinase 3 (RIPK3).” | 0.98 | hgnc_dict_v1 |
| gene | RIPK3 | “Finally, we performed theoretical studies of molecular docking, molecular dynamics and interactions between lamivudine and key proteins regulating necroptosis, including epidermal growth factor receptor (EGFR), receptor-interacting protein kinase 1 (RIPK1), and receptor-interacting protein kinase 3 (RIPK3).” | 0.98 | hgnc_dict_v1 |
Development of new anticancer thiadiazole-sulfonamides as dual EGFR/carbonic anhydrase inhibitors.
PMID 40337848 | PMCID PMC12091935 | DOI 10.1080/17568919.2025.2498879 · Future medicinal chemistry · 2025 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Development of new anticancer thiadiazole-sulfonamides as dual EGFR/carbonic anhydrase inhibitors.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “METHODS: Cytotoxicity was evaluated against MDA-MB-231 and MCF-7 breast cancer cells, with selectivity tested on Vero cells.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | BAX | “Apoptosis was assessed through gene expression analysis of BAX/Bcl-2, caspase-8, and caspase-9, alongside flow cytometry for apoptosis and cell cycle analysis.” | 0.98 | hgnc_dict_v1 |
Unleashing the anti-tumor angiogenic potential of nano-formulated orientin: In Silico, In Vitro, and In Ovo studies.
PMID 40679996 | PMCID PMC12273919 | DOI 10.1371/journal.pone.0322564 · PloS one · 2025 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “In silico docking studies, the favorable binding of orientin was identified with the key oncogenic targets (EGFR, ALK, KRAS, NTRK).” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “In-vitro studies using MCF-7 breast cancer cells showed that NF-O inhibited cell growth and reduced viability in a dose-dependent manner.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | KRAS | “In silico docking studies, the favorable binding of orientin was identified with the key oncogenic targets (EGFR, ALK, KRAS, NTRK).” | 0.98 | hgnc_dict_v1 |
Cordycepin and Its Structural Derivatives Effectively Suppress the High Expression of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase in Breast Carcinomas: A Computational Drug Development Approach.
PMID 39817386 | DOI 10.2174/0109298673333884241119063458 · Current medicinal chemistry · 2025 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Cordycepin and Its Structural Derivatives Effectively Suppress the High Expression of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase in Breast Carcinomas: A Computational Drug Development Approach.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “BACKGROUND: Breast cancer is a frequently diagnosed malignant disease and the primary cause of mortality among women with cancer worldwide.” | 0.98 | phenotype_alias_lexicon_v2 |
Tinagl1 restores tamoxifen sensitivity and blocks fibronectin-induced EMT by simultaneously blocking the EGFR and β1-integrin/FAK signaling pathways in tamoxifen-resistant breast cancer cells.
PMID 39817673 | DOI 10.1002/iub.2940 · IUBMB life · 2025 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Tinagl1 restores tamoxifen sensitivity and blocks fibronectin-induced EMT by simultaneously blocking the EGFR and β1-integrin/FAK signaling pathways in tamoxifen-resistant breast cancer cells.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Tinagl1 restores tamoxifen sensitivity and blocks fibronectin-induced EMT by simultaneously blocking the EGFR and β1-integrin/FAK signaling pathways in tamoxifen-resistant breast cancer cells.” | 0.98 | phenotype_alias_lexicon_v2 |
Pyrazole-benzimidazole derivatives targeting MCF-7 breast cancer cells as potential anti-proliferative agents. 3D QSAR and In-silico investigations via molecular docking and molecular dynamics simulations.
PMID 40068494 | DOI 10.1016/j.compbiomed.2025.109969 · Computers in biology and medicine · 2025 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “This study focuses on a predictive drug discovery strategy for compounds that may modulate interaction with HER-2 and EGFR, two important receptors in cancer treatment.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Pyrazole-benzimidazole derivatives targeting MCF-7 breast cancer cells as potential anti-proliferative agents.” | 0.98 | phenotype_alias_lexicon_v2 |
Chemoinformatics analysis of Mangifera indica leaves extracted phytochemicals as potential EGFR kinase modulators.
PMID 40196294 | PMCID PMC11973374 | DOI 10.3389/fchem.2025.1524384 · Frontiers in chemistry · 2025 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Chemoinformatics analysis of Mangifera indica leaves extracted phytochemicals as potential EGFR kinase modulators.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Breast cancer, being among the most frequent and fatal cancers in women, is an enormous issue globally.” | 0.98 | phenotype_alias_lexicon_v2 |
Emerging therapeutic strategies and opportunities in targeting protein pathways for breast cancer treatment: a critical review.
PMID 40345214 | DOI 10.1088/1361-6528/add6ae · Nanotechnology · 2025 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Examining proteins such as EGFR, HER2/Neu, and ER reveals their roles in cancer pathways, with pathways like PI3K/Akt/mTOR (phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin) and MAPK (mitogen-activated protein kinase) being crucial targets for therapies, potentially revolutionizing breast cancer treatment.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Emerging therapeutic strategies and opportunities in targeting protein pathways for breast cancer treatment: a critical review.” | 0.98 | phenotype_alias_lexicon_v2 |
Formulation and Assessment of Broccoli Extract-Infused Hydrogel for Targeted Breast Cancer Therapy.
PMID 40696561 | DOI 10.2174/0113892010373087250710035336 · Current pharmaceutical biotechnology · 2025 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “In breast cancer cell lines, SFN functions as an HDAC inhibitor and reduces the expression of ER, EGFR, & HER-2 proteins.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Formulation and Assessment of Broccoli Extract-Infused Hydrogel for Targeted Breast Cancer Therapy.” | 0.98 | phenotype_alias_lexicon_v2 |
A deep learning model for epidermal growth factor receptor prediction using ensemble residual convolutional neural network.
PMID 41023039 | PMCID PMC12480584 | DOI 10.1038/s41598-025-18518-5 · Scientific reports · 2025 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Epidermal growth factor receptor (EGFR) overexpression is a key oncogenic driver in breast cancer, making it an important therapeutic target.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Epidermal growth factor receptor (EGFR) overexpression is a key oncogenic driver in breast cancer, making it an important therapeutic target.” | 0.98 | phenotype_alias_lexicon_v2 |
Network Pharmacology and Experimental Validation to Explore the Potential Mechanism of Nigella sativa for the Treatment of Breast Cancer.
PMID 38794187 | PMCID PMC11124279 | DOI 10.3390/ph17050617 · Pharmaceuticals (Basel, Switzerland) · 2024 · 6 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Five proteins (i.e., EGFR, MAPK3, ESR1, MAPK1, and PTGS2) associated with breast cancer were selected as receptor proteins.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Network Pharmacology and Experimental Validation to Explore the Potential Mechanism of Nigella sativa for the Treatment of Breast Cancer.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | MAPK3 | “Five proteins (i.e., EGFR, MAPK3, ESR1, MAPK1, and PTGS2) associated with breast cancer were selected as receptor proteins.” | 0.98 | hgnc_dict_v1 |
| gene | ESR1 | “Five proteins (i.e., EGFR, MAPK3, ESR1, MAPK1, and PTGS2) associated with breast cancer were selected as receptor proteins.” | 0.98 | hgnc_dict_v1 |
The Multifaceted Roles of Myrrha in the Treatment of Breast Cancer: Potential Therapeutic Targets and Promises.
PMID 39707884 | PMCID PMC11663268 | DOI 10.1177/15347354241309659 · Integrative cancer therapies · 2024 · 6 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “RESULTS: Combining the results of network pharmacology with other bioinformatics databases suggests that myrrh's active components exert anti-cancer effects by regulating genes involved in breast cancer pathogenesis, particularly PTGS2, EGFR, ESR2, MMP2, and JUN.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “The Multifaceted Roles of Myrrha in the Treatment of Breast Cancer: Potential Therapeutic Targets and Promises.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | PTGS2 | “RESULTS: Combining the results of network pharmacology with other bioinformatics databases suggests that myrrh's active components exert anti-cancer effects by regulating genes involved in breast cancer pathogenesis, particularly PTGS2, EGFR, ESR2, MMP2, and JUN.” | 0.98 | hgnc_dict_v1 |
| gene | ESR2 | “RESULTS: Combining the results of network pharmacology with other bioinformatics databases suggests that myrrh's active components exert anti-cancer effects by regulating genes involved in breast cancer pathogenesis, particularly PTGS2, EGFR, ESR2, MMP2, and JUN.” | 0.98 | hgnc_dict_v1 |
Exploring EGFR inhibitors with the aid of virtual screening, docking, and dynamics simulation studies.
PMID 37707987 | DOI 10.1080/07391102.2023.2256887 · Journal of biomolecular structure & dynamics · 2024 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Exploring EGFR inhibitors with the aid of virtual screening, docking, and dynamics simulation studies.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “In humans, Epidermal Growth Factor Receptor (EGFR) is linked to small-cell lung cancer, breast cancer, and glioblastoma.” | 0.98 | phenotype_alias_lexicon_v2 |
| phenotype | lung cancer | “In humans, Epidermal Growth Factor Receptor (EGFR) is linked to small-cell lung cancer, breast cancer, and glioblastoma.” | 0.98 | phenotype_alias_lexicon_v2 |
Exploring pyrrolidinyl-spirooxindole natural products as promising platforms for the synthesis of novel spirooxindoles as EGFR/CDK2 inhibitors for halting breast cancer cells.
PMID 38487783 | PMCID PMC10937419 | DOI 10.3389/fchem.2024.1364378 · Frontiers in chemistry · 2024 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Exploring pyrrolidinyl-spirooxindole natural products as promising platforms for the synthesis of novel spirooxindoles as EGFR/CDK2 inhibitors for halting breast cancer cells.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Exploring pyrrolidinyl-spirooxindole natural products as promising platforms for the synthesis of novel spirooxindoles as EGFR/CDK2 inhibitors for halting breast cancer cells.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | CDK2 | “Exploring pyrrolidinyl-spirooxindole natural products as promising platforms for the synthesis of novel spirooxindoles as EGFR/CDK2 inhibitors for halting breast cancer cells.” | 0.98 | hgnc_dict_v1 |
New apoptotic anti-triple-negative breast cancer theobromine derivative inhibiting EGFRWT and EGFRT790M: in silico and in vitro evaluation.
PMID 37162644 | DOI 10.1007/s11030-023-10644-4 · Molecular diversity · 2024 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “A new theobromine-derived EGFR inhibitor (2-(3,7-Dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)-N-(2,6-dimethylphenyl)acetamide) has been developed that has the essential structural characteristics to interact with EGFR's pocket.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “New apoptotic anti-triple-negative breast cancer theobromine derivative inhibiting EGFRWT and EGFRT790M: in silico and in vitro evaluation.” | 0.98 | phenotype_alias_lexicon_v2 |
Rational design and eco-friendly one-pot multicomponent synthesis of novel ethylidenehydrazineylthiazol-4(5H)-ones as potential apoptotic inducers targeting wild and mutant EGFR-TK in triple negative breast cancer.
PMID 37890211 | DOI 10.1016/j.bioorg.2023.106936 · Bioorganic chemistry · 2024 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “The frontier anticancer candidates against the MDA-MB-468 were also examined against the wild EGFR (EGFR-WT) and mutant EGFR (EGFR-T790M) receptors.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Rational design and eco-friendly one-pot multicomponent synthesis of novel ethylidenehydrazineylthiazol-4(5H)-ones as potential apoptotic inducers targeting wild and mutant EGFR-TK in triple negative breast cancer.” | 0.98 | phenotype_alias_lexicon_v2 |
Biological evaluation, docking studies, and in silico ADME prediction of some pyrimidine and pyridine derivatives as potential EGFRWT and EGFRT790M inhibitors.
PMID 36317648 | PMCID PMC9635468 | DOI 10.1080/14756366.2022.2135512 · Journal of enzyme inhibition and medicinal chemistry · 2023 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Furthermore, compounds 8 and 14 were assessed for their EGFR kinase (Wild and T790M) inhibitory activities, revealing eligible potential.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Human breast cancer (MCF7), hepatocellular carcinoma (HEPG2), larynx cancer (HEP2), lung cancer (H460), colon cancers (HCT116 and Caco2), and hypopharyngeal cancer (FADU), and normal Vero cell lines were used.” | 0.98 | phenotype_alias_lexicon_v2 |
| phenotype | lung cancer | “Human breast cancer (MCF7), hepatocellular carcinoma (HEPG2), larynx cancer (HEP2), lung cancer (H460), colon cancers (HCT116 and Caco2), and hypopharyngeal cancer (FADU), and normal Vero cell lines were used.” | 0.98 | phenotype_alias_lexicon_v2 |
| phenotype | hepatocellular carcinoma | “Human breast cancer (MCF7), hepatocellular carcinoma (HEPG2), larynx cancer (HEP2), lung cancer (H460), colon cancers (HCT116 and Caco2), and hypopharyngeal cancer (FADU), and normal Vero cell lines were used.” | 0.98 | phenotype_alias_lexicon_v2 |
Network pharmacology and molecular docking study for biological pathway detection of cytotoxicity of the yellow jasmine flowers.
PMID 37210476 | PMCID PMC10199617 | DOI 10.1186/s12906-023-03987-w · BMC complementary medicine and therapies · 2023 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Relationship between compounds, target genes, and pathways revealed that J. humile exerts its effect on breast cancer by altering, Estrogen signaling pathway, HER2, and EGFR overexpression.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Furthermore, we assessed the cytotoxic activity of the flower extract against breast cancer (MCF-7) cell line using MTT assay followed by the cell cycle, DNA-flow cytometry, and Annexin V-FITC analyses alongside the effect on reactive oxygen species (ROS).” | 0.98 | phenotype_alias_lexicon_v2 |
Synthesis and SARs study of novel spiro-oxindoles as potent antiproliferative agents with CDK-2 inhibitory activities.
PMID 37253118 | DOI 10.1002/ardp.202300185 · Archiv der Pharmazie · 2023 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Compound 8c was investigated for epidermal growth factor receptor (EGFR) inhibition; it exhibited promising IC50 values of 96.6 nM compared with 67.3 nM for erlotinib.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “The potency of all compounds was assayed against a human breast cancer cell line (MCF-7) and a human liver cell line (HepG2).” | 0.98 | phenotype_alias_lexicon_v2 |
Implementation of Next-Generation Sequencing in Saudi Arabia for HER2-Positive Breast Cancer.
PMID 35280536 | PMCID PMC8913378 | DOI 10.1016/j.sjbs.2021.10.044 · Saudi journal of biological sciences · 2022 · 6 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “We also detected mutations in other genes, including BRAF, EGFR, and KRAS.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Implementation of Next-Generation Sequencing in Saudi Arabia for HER2-Positive Breast Cancer.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | PIK3CA | “We used TruSight Tumor 15 using Next-Generation Sequencing (NGS) to look at genetic changes in 126 Saudi women with stage I to IV breast cancer. c-MET (p = 0.001), c-KIT (p = 0.001), and PIK3CA (p = 0.0001), were shown to be substantially linked with HER2 positive patients.” | 0.98 | hgnc_dict_v1 |
| gene | BRAF | “We also detected mutations in other genes, including BRAF, EGFR, and KRAS.” | 0.98 | hgnc_dict_v1 |
A review on epidermal growth factor receptor's role in breast and non-small cell lung cancer.
PMID 34742684 | DOI 10.1016/j.cbi.2021.109735 · Chemico-biological interactions · 2022 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Epithelial growth factor receptor (EGFR) is a cell surface transmembrane receptor that mediates the tyrosine signaling pathway to carry the extracellular messages inside the cell and thereby alter the function of nucleus.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “It belongs to the HER-2 receptor-family in breast cancer and responds best with anti-Herceptin therapy (anti-tyrosine kinase monoclonal antibody).” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | ERBB2 | “It is encoded by cell erythroblastosis virus oncogene B1, so called C-erb B1/ERBB2/HER-2 gene that acts as a proto-oncogene.” | 0.98 | hgnc_dict_v1 |
| gene | EGF | “Present study highlights the role and connectivity of EGF with various cancers via signaling pathways, cell surface receptors mechanism, macromolecules, mitochondrial genes and neoplasm.” | 0.98 | hgnc_dict_v1 |
Pharmacophore-based virtual screening approaches to identify novel molecular candidates against EGFR through comprehensive computational approaches and in-vitro studies.
PMID 36457709 | PMCID PMC9707641 | DOI 10.3389/fphar.2022.1027890 · Frontiers in pharmacology · 2022 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Pharmacophore-based virtual screening approaches to identify novel molecular candidates against EGFR through comprehensive computational approaches and in-vitro studies.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “MTT assay, gene expression analysis (BAX, BCL-2, and β-catenin), apoptosis analysis, TEM, cell cycle assay, ELISA, and cell migration assays were conducted to perform the cell death analysis of lung cancer and breast cancer, compared to the marketed product.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | BAX | “MTT assay, gene expression analysis (BAX, BCL-2, and β-catenin), apoptosis analysis, TEM, cell cycle assay, ELISA, and cell migration assays were conducted to perform the cell death analysis of lung cancer and breast cancer, compared to the marketed product.” | 0.98 | hgnc_dict_v1 |
| phenotype | lung cancer | “Alterations to the EGFR (epidermal growth factor receptor) gene, which primarily occur in the axon 18-21 position, have been linked to a variety of cancers, including ovarian, breast, colon, and lung cancer.” | 0.98 | phenotype_alias_lexicon_v2 |
Unraveling the differential impact of PAHs and dioxin-like compounds on AKR1C3 reveals the EGFR extracellular domain as a critical determinant of the AHR response.
PMID 34991250 | PMCID PMC8852774 | DOI 10.1016/j.envint.2021.106989 · Environment international · 2022 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Unraveling the differential impact of PAHs and dioxin-like compounds on AKR1C3 reveals the EGFR extracellular domain as a critical determinant of the AHR response.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “By elucidating the differential effects of PAHs and DLCs on aldo-keto reductase 1C3 expression and associated prostaglandin D2 metabolism, we here provide evidence that the epidermal growth factor receptor (EGFR) substantially shapes AHR ligand-induced responses in human epithelial cells, i.e. primary and immortalized keratinocytes and breast cancer cells.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | AKR1C3 | “Unraveling the differential impact of PAHs and dioxin-like compounds on AKR1C3 reveals the EGFR extracellular domain as a critical determinant of the AHR response.” | 0.98 | hgnc_dict_v1 |
Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer.
PMID 35124721 | PMCID PMC8960565 | DOI 10.1007/s10549-022-06531-5 · Breast cancer research and treatment · 2022 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “There was a positive correlation between high UBE2C protein expression and cell cycle-associated biomarkers, p53, Ki67, EGFR and PI3K.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | UBE2C | “Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer.” | 0.98 | hgnc_dict_v1 |
Recent Advances of Nanotechnology in the Diagnosis and Therapy of Triple- Negative Breast Cancer (TNBC).
PMID 34967294 | DOI 10.2174/1389201023666211230113658 · Current pharmaceutical biotechnology · 2022 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “OBJECTIVE: The current review introduced the novel biomarkers such as miRNA and family, PD1, EGFR, VEGF, TILs, P53, AR and PI3K, etc. contributed significantly to the prognosis and diagnosis of TNBC.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Recent Advances of Nanotechnology in the Diagnosis and Therapy of Triple- Negative Breast Cancer (TNBC).” | 0.98 | phenotype_alias_lexicon_v2 |
Post-transcriptional screen of cancer amplified genes identifies ERBB2/Her2 signaling as AU-rich mRNA stability-promoting pathway.
PMID 34535639 | PMCID PMC8448767 | DOI 10.1038/s41389-021-00351-w · Oncogenesis · 2021 · 9 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Screening for the impact of other amplified cancer genes in HEK293 cells also demonstrated that EGFR, AKT2, CCND1, CCNE1, SKP2, and FGFR3 caused both increased abundance of phosphorylated ZFP36/TTP and ARE-post-transcriptional reporter activity.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “The ERBB1/2 inhibitor, lapatinib, led to the reversal of the aberrant ARE-mediated process in ERBB2-amplified breast cancer cells.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | ERBB2 | “Post-transcriptional screen of cancer amplified genes identifies ERBB2/Her2 signaling as AU-rich mRNA stability-promoting pathway.” | 0.98 | hgnc_dict_v1 |
| gene | ZFP36 | “The ERBB2 inhibitor decreased both the abundance and stability of the phosphorylated inactive form of the mRNA decay-promoting protein, tristetraprolin (ZFP36/TTP).” | 0.98 | hgnc_dict_v1 |
New pyrimidine and pyrazole-based compounds as potential EGFR inhibitors: Synthesis, anticancer, antimicrobial evaluation and computational studies.
PMID 34161878 | DOI 10.1016/j.bioorg.2021.105078 · Bioorganic chemistry · 2021 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “New pyrimidine and pyrazole-based compounds as potential EGFR inhibitors: Synthesis, anticancer, antimicrobial evaluation and computational studies.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “The new compounds were assessed as cytotoxic candidates against human breast cancer cells (MCF-7) and hepatocellular carcinoma cells (HepG-2).” | 0.98 | phenotype_alias_lexicon_v2 |
| phenotype | hepatocellular carcinoma | “The new compounds were assessed as cytotoxic candidates against human breast cancer cells (MCF-7) and hepatocellular carcinoma cells (HepG-2).” | 0.98 | phenotype_alias_lexicon_v2 |
Epigenetic immunomodulatory effect of eugenol and astaxanthin on doxorubicin cytotoxicity in hormonal positive breast Cancer cells.
PMID 33509300 | PMCID PMC7842008 | DOI 10.1186/s40360-021-00473-2 · BMC pharmacology & toxicology · 2021 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Combinations of DOX with 1 mM EUG or 40 μM AST significantly increased the level of histones acetylation and histone acetyl transferase expression, while reduced the expression of aromatase and epidermal growth factor receptor (EGFR) when compared with 0.25 μM DOX alone.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Epigenetic immunomodulatory effect of eugenol and astaxanthin on doxorubicin cytotoxicity in hormonal positive breast Cancer cells.” | 0.98 | phenotype_alias_lexicon_v2 |
Discovering novel cancer bio-markers in acquired lapatinib resistance using Bayesian methods.
PMID 33857297 | DOI 10.1093/bib/bbab137 · Briefings in bioinformatics · 2021 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “This project, namely 'PathTurbEr' (Pathway Perturbation Driver) uses the GE dataset derived from the lapatinib (an EGFR/HER dual inhibitor) sensitive and resistant samples from breast cancer cell lines (SKBR3).” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “This project, namely 'PathTurbEr' (Pathway Perturbation Driver) uses the GE dataset derived from the lapatinib (an EGFR/HER dual inhibitor) sensitive and resistant samples from breast cancer cell lines (SKBR3).” | 0.98 | phenotype_alias_lexicon_v2 |
Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysis.
PMID 33918859 | PMCID PMC8068962 | DOI 10.3390/genes12040549 · Genes · 2021 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Herein, we identified significant differentially expressed circulating miRNAs in TNBC patients (miR-19a/b-3p, miR-25-3p, miR-22-3p, miR-210-3p, miR-93-5p, and miR-199a-3p) that regulate several molecular pathways (PAM (PI3K/Akt/mTOR), HIF-1, TNF, FoxO, Wnt, and JAK/STAT, PD-1/PD-L1 pathways and EGFR tyrosine kinase inhibitor resistance (TKIs)) involved in drug resistance.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysis.” | 0.98 | phenotype_alias_lexicon_v2 |
In Silico Screening of Marine Compounds as an Emerging and Promising Approach against Estrogen Receptor Alpha-Positive Breast Cancer.
PMID 34957309 | PMCID PMC8709776 | DOI 10.1155/2021/9734279 · BioMed research international · 2021 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Our in silico approach analysis offers a pharmacoinformatics methodology for identifying lead molecules targeting cochaperone HSP90 and the epidermal growth factor receptors (EGFR) and human epidermal growth factor receptor 2 (HER2)/neu receptor.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “In Silico Screening of Marine Compounds as an Emerging and Promising Approach against Estrogen Receptor Alpha-Positive Breast Cancer.” | 0.98 | phenotype_alias_lexicon_v2 |
Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival.
PMID 32445177 | PMCID PMC7297818 | DOI 10.1007/s10549-020-05670-x · Breast cancer research and treatment · 2020 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Elevated MMP9 protein expression correlated significantly with cytokeratin 17 (Ck17), Epidermal Growth Factor Receptor (EGFR), proliferation (Ki67) biomarkers, cell surface adhesion receptor (CD44) and cell division control protein 42 (CDC42).” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | MMP9 | “Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival.” | 0.98 | hgnc_dict_v1 |
| gene | CD44 | “Elevated MMP9 protein expression correlated significantly with cytokeratin 17 (Ck17), Epidermal Growth Factor Receptor (EGFR), proliferation (Ki67) biomarkers, cell surface adhesion receptor (CD44) and cell division control protein 42 (CDC42).” | 0.98 | hgnc_dict_v1 |
3'-(4-(Benzyloxy)phenyl)-1'-phenyl-5-(heteroaryl/aryl)-3,4-dihydro-1'H,2H-[3,4'-bipyrazole]-2-carboxamides as EGFR kinase inhibitors: Synthesis, anticancer evaluation, and molecular docking studies.
PMID 32003485 | DOI 10.1002/ardp.201900262 · Archiv der Pharmazie · 2020 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “3'-(4-(Benzyloxy)phenyl)-1'-phenyl-5-(heteroaryl/aryl)-3,4-dihydro-1'H,2H-[3,4'-bipyrazole]-2-carboxamides as EGFR kinase inhibitors: Synthesis, anticancer evaluation, and molecular docking studies.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Some of these compounds showed effects on proliferation, which were also then evaluated against four different human cancer cell lines, that is, MCF-7 (breast cancer), A549 (non-small-cell lung tumor), HCT-116 (colon cancer), and SiHa cells (cancerous tissues of the cervix uteri).” | 0.98 | phenotype_alias_lexicon_v2 |
| phenotype | cardiomyopathy | “Pyrazoline-linked carboxamide derivatives were designed, synthesized, and evaluated for potential epidermal growth factor receptor (EGFR) kinase inhibition, anticancer activity, and apoptotic and cardiomyopathy toxicity.” | 0.98 | phenotype_alias_lexicon_v2 |
| phenotype | colorectal cancer | “Some of these compounds showed effects on proliferation, which were also then evaluated against four different human cancer cell lines, that is, MCF-7 (breast cancer), A549 (non-small-cell lung tumor), HCT-116 (colon cancer), and SiHa cells (cancerous tissues of the cervix uteri).” | 0.93 | phenotype_alias_lexicon_v2 |
Novel quinazoline-based EGFR kinase inhibitors: A review focussing on SAR and molecular docking studies (2015-2019).
PMID 32739648 | DOI 10.1016/j.ejmech.2020.112640 · European journal of medicinal chemistry · 2020 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Novel quinazoline-based EGFR kinase inhibitors: A review focussing on SAR and molecular docking studies (2015-2019).” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “The over expression of EGFR has been recognized as the driver mechanism in the occurrence and progression of carcinomas such as lung cancer, breast cancer, pancreatic cancer, etcetera.” | 0.98 | phenotype_alias_lexicon_v2 |
| phenotype | lung cancer | “The over expression of EGFR has been recognized as the driver mechanism in the occurrence and progression of carcinomas such as lung cancer, breast cancer, pancreatic cancer, etcetera.” | 0.98 | phenotype_alias_lexicon_v2 |
| variant | C797S | “Newer mutations like C797S cause failure of Osimertinib and other EGFR TKIs belonging to the third-generation caused by the development of resistance.” | 0.82 | literature_variant_regex_v2 |
Evaluation of lapatinib cytotoxicity and genotoxicity on MDA-MB-231 breast cancer cell line.
PMID 31234033 | DOI 10.1016/j.etap.2019.103207 · Environmental toxicology and pharmacology · 2019 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “We investigated the cytotoxicity of lapatinib by MTT assay, mode of cell death using apoptosis-necrosis assay, DNA damage using micronucleus test, EGFR protein expression by immunocytochemistry, and assessed its effect on EGFR (7p11.2 locus) and TP53 (17p13 locus) genes using interphase-FISH technique.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Evaluation of lapatinib cytotoxicity and genotoxicity on MDA-MB-231 breast cancer cell line.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | TP53 | “We investigated the cytotoxicity of lapatinib by MTT assay, mode of cell death using apoptosis-necrosis assay, DNA damage using micronucleus test, EGFR protein expression by immunocytochemistry, and assessed its effect on EGFR (7p11.2 locus) and TP53 (17p13 locus) genes using interphase-FISH technique.” | 0.98 | hgnc_dict_v1 |
Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients.
PMID 28029660 | PMCID PMC5354910 | DOI 10.18632/oncotarget.14144 · Oncotarget · 2017 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “The expression of Cytokeratins (CK), ER, PR, EGFR and HER2 on CTCs was assessed using immunofluoresence staining and ARIOL analysis.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients.” | 0.98 | phenotype_alias_lexicon_v2 |
A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer.
PMID 29091754 | DOI 10.1016/j.celrep.2017.10.015 · Cell reports · 2017 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Therapies targeting epidermal growth factor receptor (EGFR) have variable and unpredictable responses in breast cancer.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer.” | 0.98 | phenotype_alias_lexicon_v2 |
Abstracts from the 3rd International Genomic Medicine Conference (3rd IGMC 2015) : Jeddah, Kingdom of Saudi Arabia. 30 November - 3 December 2015.
PMID 27454254 | PMCID PMC4959372 | DOI 10.1186/s12864-016-2858-0 · BMC genomics · 2016 · 46 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Ba-Hammam, Mohammad Athar P112 Epithelial ovarian carcinoma (EOC): Systems oncological approach to identify diagnostic, prognostic and therapeutic biomarkers Gauthaman Kalamegam, Peter Natesan Pushparaj, Muhammad Abu-Elmagd, Farid Ahmed Khalid HussainWali Sait, Nisreen Anfinan, Mamdooh Gari, Adeel Chaudhary, Adel Abuzenadah, Mourad Assidi, Mohammed Al-Qahtani P113 Crohn’s disease phenotype in northern Tunisian population Naira Ben Mami, Yosr Z Haffani, Mouna Medhioub, Lamine Hamzaoui, Ameur Cherif, Msadok Azouz P114 Establishment of In Silico approaches to decipher the potential toxicity and mechanism of action of drug candidates and environmental agents Gauthaman Kalamegam, Fazal Khan, Shilu Mathew, Mohammed Imran Nasser, Mahmood Rasool, Farid Ahmed, Peter Natesan Pushparaj, Mohammed Al-Qahtani P115 1q Gain predicts poor prognosis marker for young breast cancer patients Shereen A Turkistany, Lina M Al-harbi, Ashraf Dallol, Jamal Sabir, Adeel Chaudhary, Adel Abuzenadah P116 Disorders of sex chromosomes in a diagnostic genomic medicine unit in Saudi Arabia: Prevalence, diagnosis and future guidelines Basmah Al-Madoudi, Bayan Al-Aslani, Khulud Al-Harbi, Rwan Al-Jahdali, Hanadi Qudaih, Emad Al Hamzy, Mourad Assidi, Mohammed Al Qahtani P117 Combination of WYE354 and Sunitinib demonstrate synergistic inhibition of acute myeloid leukemia in vitro Asad M Ilyas, Youssri Ahmed, Mamdooh Gari, Farid Ahmed, Mohammed Alqahtani P118 Integrated use of evolutionary information in GWAS reveals important SNPs in Asthma Nada Salem, Sajjad Karim, Elham M Alhathli, Heba Abusamra, Hend F Nour Eldin, Mohammed H Al-Qahtani, Sudhir Kumar P119 Assessment of BRAF, IDH1, IDH2, and EGFR mutations in a series of primary brain tumors Fatima Al-Adwani, Deema Hussein, Mona Al-Sharif, Awatif Jamal, Fahad Al-Ghamdi, Jaudah Al-Maghrabi, Saleh S Baeesa, Mohammed Bangash, Adeel Chaudhary, Mohammed Al-Qahtani, Hans-Juergen Schulten P120 Expression profiles distinguish oligodendrogliomas from glioblastoma multiformes with or without oligodendroglioma component Alaa Alamandi, Reem Alotibi, Deema Hussein, Sajjad Karim, Jaudah Al-Maghrabi, Fahad Al-Ghamdi, Awatif Jamal, Saleh S Baeesa, Mohammed Bangash, Adeel Chaudhary, Hans-Juergen Schulten, Mohammed Al-Qahtani P121 Hierarchical clustering in thyroid goiters and hyperplastic lesions Ohoud Subhi, Nadia Bagatian, Sajjad Karim, Adel Al-Johari, Osman Abdel Al-Hamour, Hosam Al-Aradati, Abdulmonem Al-Mutawa, Faisal Al-Mashat, Jaudah Al-Maghrabi, Hans-Juergen Schulten, Mohammad Al-Qahtani P122 Differential expression analysis in thyroiditis and papillary thyroid carcinomas with or without coexisting thyroiditis Nadia Bagatian, Ohoud Subhi, Sajjad Karim, Adel Al-Johari, Osman Abdel Al-Hamour, Abdulmonem Al-Mutawa, Hosam Al-Aradati, Faisal Al-Mashat, Mohammad Al-Qahtani, Hans-Juergen Schulten, Jaudah Al-Maghrabi P123 Metagenomic analysis of waste water microbiome in Sausdi Arabia Muhammad W shah, Muhammad Yasir, Esam I Azhar, Saad Al-Masoodi P124 Molecular characterization of Helicobacter pylori from faecal samples of Tunisian patients with gastric cancer Yosr Z Haffani, Msadok Azouz, Emna Khamla, Chaima Jlassi, Ahmed S.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Al-Qahtani O19 A new look to reproductive medicine in the era of genomics Serdar Coskun P1 Wnt signalling receptors expression in Saudi breast cancer patients Muhammad Abu-Elmagd, Abdelbaset Buhmeida, Ashraf Dallol, Jaudah Al-Maghrabi, Sahar Hakamy, Wejdan Al-Qahtani, Asia Al-Harbi, Shireen Hussain, Mourad Assidi, Mohammed Al-Qahtani, Adel Abuzenadah P2 Analysis of oxidative stress interactome during spermatogenesis: a systems biology approach to reproduction Burak Ozkosem, Rick DuBois P3 Interleukin-18 gene variants are strongly associated with idiopathic recurrent pregnancy loss.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | KIF2A | “Shay O2 The microtubule destabilizer KIF2A regulates the postnatal establishment of neuronal circuits in addition to prenatal cell survival, cell migration, and axon elongation, and its loss leading to malformation of cortical development and severe epilepsy Noriko Homma, Ruyun Zhou, Muhammad Imran Naseer, Adeel G.” | 0.98 | hgnc_dict_v1 |
| gene | RPL27A | “Saini, Awatif Jamal, Jaudah Al-Maghrabi, Adel Abuzenadah, Adeel Chaudhary, Mohammed Al Qahtani, Ghazi Damanhouri O5 RPL27A is a target of miR-595 and deficiency contributes to ribosomal dysgenesis Heba Alkhatabi O6 Next generation DNA sequencing panels for haemostatic and platelet disorders and for Fanconi anaemia in routine diagnostic service Anne Goodeve, Laura Crookes, Nikolas Niksic, Nicholas Beauchamp O7 Targeted sequencing panels and their utilization in personalized medicine Adel M.” | 0.98 | hgnc_dict_v1 |
HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer.
PMID 25435280 | PMCID PMC4815926 | DOI 10.1016/j.molonc.2014.10.011 · Molecular oncology · 2015 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Because mutations within HER1/EGFR are predictive of response to tyrosine kinase inhibitors (TKI) in lung cancer, we investigated whether mutations in HER family kinase domains are predictive of response to targeted therapy in HER2-overexpressing breast cancer.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer.” | 0.98 | phenotype_alias_lexicon_v2 |
| phenotype | lung cancer | “Because mutations within HER1/EGFR are predictive of response to tyrosine kinase inhibitors (TKI) in lung cancer, we investigated whether mutations in HER family kinase domains are predictive of response to targeted therapy in HER2-overexpressing breast cancer.” | 0.98 | phenotype_alias_lexicon_v2 |
Metaplastic carcinoma of the breast: an immunohistochemical study.
PMID 25030022 | PMCID PMC4223421 | DOI 10.1186/1746-1596-9-139 · Diagnostic pathology · 2014 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Cases were studied immunohistochemically by CK-Pan, Vimentin, ER, PR, HER2, basal markers (CK5/6, p63, EGFR, SMA and S-100), luminal cytokeratins (CK8, CK18 and CK19), markers for syncytial cells (β-HCG and PLAP), as well as prognostic markers (p53, ki-67 and calretinin).” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “BACKGROUND: Metaplastic breast carcinoma is a rare entity of breast cancer expressing epithelial and/or mesenchymal tissue within the same tumor.” | 0.98 | phenotype_alias_lexicon_v2 |
Very low prevalence of epidermal growth factor receptor (EGFR) protein expression and gene amplification in Saudi breast cancer patients.
PMID 21702909 | PMCID PMC3141623 | DOI 10.1186/1746-1596-6-57 · Diagnostic pathology · 2011 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Very low prevalence of epidermal growth factor receptor (EGFR) protein expression and gene amplification in Saudi breast cancer patients.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Very low prevalence of epidermal growth factor receptor (EGFR) protein expression and gene amplification in Saudi breast cancer patients.” | 0.98 | phenotype_alias_lexicon_v2 |
| population | Saudi Arabia | “Very low prevalence of epidermal growth factor receptor (EGFR) protein expression and gene amplification in Saudi breast cancer patients. Studies addressing EGFR protein expression and gene amplification in Saudi breast cancer patients are extremely scanty and the results reported have been mostly non-conclusive. Herein we report the prevalence of EGFR protein expression and gene amplification in a cohort of Saudi breast cancer patients. FINDINGS: We noticed a remarkably low incidence of EGFR protein expression (1.3%) while analyzing the spectrum of molecular subtypes of breast cancer in a Saudi population by immunohistochemistry. Also, EGFR gene amplification could not be demonstrated in any of 231 cases studied using silver enhanced in situ hybridization. CONCLUSIONS: The extremely low incidence of EGFR protein expression and gene amplification in Saudi breast cancer patients as compared to Western populations is most probably ethnically related as supported by our previous finding in the same cohort of a spectrum of molecular breast cancer types that is unique to the Saudi population and in stark contrast with Western and other regionally based studies. Further support to this view is provided by earlier studies from Saudi Arabia that have similarly shown variability in molecular breast cancer subtype distribution between Saudi and Caucasian populations as well as a predominance of the high-grade pathway in breast cancer development in Middle East women. More studies on EGFR in breast cancer are needed from different regions of Saudi Arabia before our assumption can be confirmed, however.” | 0.95 | saudi_context_rules_v1 |
Protein expression profile and prevalence pattern of the molecular classes of breast cancer--a Saudi population based study.
PMID 20492711 | PMCID PMC2880995 | DOI 10.1186/1471-2407-10-223 · BMC cancer · 2010 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “ER, PR, HER2, EGFR and CK5/6 were used as surrogate markers for gene expression profiling to classify 231 breast cancer specimens.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “BACKGROUND: Breast cancer is not a single entity but a diverse group of entities.” | 0.98 | phenotype_alias_lexicon_v2 |
| population | Saudi Arabia | “Protein expression profile and prevalence pattern of the molecular classes of breast cancer--a Saudi population based study. METHODS: We aimed to analyze the spectrum of molecular subtypes present in the Saudi population. RESULTS: Out of 231 cases 9 (3.9%) were classified as luminal A (strong ER +ve, PR +ve or -ve), 37 (16%) as luminal B (weak to moderate ER +ve, and/or PR +ve), 40 (17.3%) as HER2+ (strong or moderately positive HER 2 with confirmation by silver enhanced in-situ hybridization) and 23 (10%) as basal (CK5/6 or EGFR +ve).” | 0.95 | saudi_context_rules_v1 |
HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer.
PMID 16882699 | PMCID PMC1995777 | DOI 10.1136/jcp.2006.038281 · Journal of clinical pathology · 2007 · 6 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Remarkably, there were four tumours exhibiting classic high-level gene amplification for HER2 (Swiss 1.3%), a pattern often accompanied by response to trastuzumab (Herceptin) in breast cancer.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | TOP2A | “HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer.” | 0.98 | hgnc_dict_v1 |
| gene | CCND1 | “HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer.” | 0.98 | hgnc_dict_v1 |
Predominance of high-grade pathway in breast cancer development of Middle East women.
PMID 15803183 | DOI 10.1038/modpathol.3800408 · Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2005 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Tissue microarrays were analyzed by fluorescence in situ hybridization for HER2, CCND1, MYC, and EGFR amplification.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Predominance of high-grade pathway in breast cancer development of Middle East women.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | CCND1 | “Tissue microarrays were analyzed by fluorescence in situ hybridization for HER2, CCND1, MYC, and EGFR amplification.” | 0.98 | hgnc_dict_v1 |
| population | Saudi Arabia | “To identify potential molecular differences between breast cancers in Europe and the Middle East, we analyzed consecutive breast cancer series from Switzerland (n=2197) and Saudi Arabia (n=204). The data revealed marked differences between Saudi and Swiss patients. Saudi breast cancers had a markedly higher frequency of HER2 (31 vs 17%; P<0.0001) and MYC (16 vs 5%; P<0.0001) amplifications than Swiss breast cancers. Remarkably, this was partly due to a much higher incidence of grade 3 cancers in the Saudi than in the Swiss population (65 vs 32%; P<0.0001). Interestingly, in combination with known age standardized incidence rates of breast cancer in Saudi Arabia (21.6/100 000) and Switzerland (70.1/100 000), these data suggest that the incidence of high-grade breast cancer is comparable for Saudi and Swiss women, while the incidence of low-grade breast cancers is about 14 times lower in Saudi than for Swiss women. These observations suggest that a difference in genetic susceptibility and/or lifestyle between Saudi and Swiss women has a substantial and much higher than expected impact on the risk of low-grade breast cancer.” | 0.95 | saudi_context_rules_v1 |
Transient transfection of epidermal growth factor receptor gene into MCF7 breast ductal carcinoma cell line.
PMID 15584089 | DOI 10.1002/cbf.1186 · Cell biochemistry and function · 2005 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Epidermal growth factor receptor (EGFR) is activated by autocrine growth factors in many types of tumours, including breast tumours.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “This receptor has been linked to a poor prognosis in breast cancer and may promote proliferation, migration, invasion, and cell survival as well as inhibition of apoptosis.” | 0.98 | phenotype_alias_lexicon_v2 |
Prognostic relevance of gene amplifications and coamplifications in breast cancer.
PMID 15574759 | DOI 10.1158/0008-5472.CAN-04-1945 · Cancer research · 2004 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | EGFR | “Multiple different oncogenes have been described previously to be amplified in breast cancer including HER2, EGFR, MYC, CCND1, and MDM2.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Prognostic relevance of gene amplifications and coamplifications in breast cancer.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | CCND1 | “Multiple different oncogenes have been described previously to be amplified in breast cancer including HER2, EGFR, MYC, CCND1, and MDM2.” | 0.98 | hgnc_dict_v1 |
| gene | MDM2 | “Multiple different oncogenes have been described previously to be amplified in breast cancer including HER2, EGFR, MYC, CCND1, and MDM2.” | 0.98 | hgnc_dict_v1 |